Mark A. McPartland

Mark A. McPartland is the current Vice President of Corporate Development at VistaGen Therapeutics. Prior to their current position, McPartland served as the Vice President of Corporate Development & Communications at Stellar Biotechnologies, Inc. from November 2013 to September 2016.

Stellar Biotechnologies, Inc. is a company that focuses on the sustainable manufacture of Keyhole Limpet Hemocyanin (KLH). KLH is an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's and inflammatory diseases) as well as a finished product for measuring immune status.

McPartland was responsible for many aspects of the company during their time there, including but not limited to corporate development and communications. Mark was instrumental in the growth of the company and helped pave the way for future success.

Mark A. McPartland has a Bachelor’s Degree in Business Administration / Marketing from Coastal Carolina University. Mark also attended the University of Nebraska at Lincoln and St. Albert.

Mark A. McPartland reports to Jerrold D. Dotson, VP, CFO & Secretary. Some of their coworkers include Mark Flather - VP, Investor Relations.